Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01159067 · OUTCOME

Number of Patients With Elevated Labile Plasma Iron (LPI) Above Threshold (0.5 Umol/L)

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload · Source last updated 2019-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
At baseline

Groups in this outcome

Arm I

Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I1

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
groups
  1. description
    Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
    id
    OG000
    title
    Arm I
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
At baseline
title
Number of Patients With Elevated Labile Plasma Iron (LPI) Above Threshold (0.5 Umol/L)
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice